These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33313306)

  • 1. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19.
    Kumar R; Lee MH; Mickael C; Kassa B; Pasha Q; Tuder R; Graham B
    ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33313306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
    Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
    J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From SARS-CoV to SARS-CoV2: a potential guide to better understanding of pathophysiology of the disease and potential therapeutic modality.
    Abbasi Pashaki P; Habibi Roudkenar M; Rahim F; Ebrahimi A
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7816-7825. PubMed ID: 32744709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
    Alnefaie A; Albogami S
    Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.
    Hejenkowska ED; Mitash N; Donovan JE; Chandra A; Bertrand C; De Santi C; Greene CM; Mu F; Swiatecka-Urban A
    J Innate Immun; 2023; 15(1):629-646. PubMed ID: 37579743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
    Sharma RK; Stevens BR; Obukhov AG; Grant MB; Oudit GY; Li Q; Richards EM; Pepine CJ; Raizada MK
    Hypertension; 2020 Sep; 76(3):651-661. PubMed ID: 32783758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection.
    Han K; Blair RV; Iwanaga N; Liu F; Russell-Lodrigue KE; Qin Z; Midkiff CC; Golden NA; Doyle-Meyers LA; Kabir ME; Chandler KE; Cutrera KL; Ren M; Monjure CJ; Lehmicke G; Fischer T; Beddingfield B; Wanek AG; Birnbaum A; Maness NJ; Roy CJ; Datta PK; Rappaport J; Kolls JK; Qin X
    Am J Respir Cell Mol Biol; 2021 Jan; 64(1):79-88. PubMed ID: 32991819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
    Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
    PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
    Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E
    Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.
    Saponaro F; Rutigliano G; Sestito S; Bandini L; Storti B; Bizzarri R; Zucchi R
    Front Mol Biosci; 2020; 7():588618. PubMed ID: 33195436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis.
    Xu J; Xu X; Jiang L; Dua K; Hansbro PM; Liu G
    Respir Res; 2020 Jul; 21(1):182. PubMed ID: 32664949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
    Asrani P; Hasan GM; Sohal SS; Hassan MI
    OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
    Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
    Front Immunol; 2020; 11():552925. PubMed ID: 33072093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses.
    Kushwaha PK; Kumari N; Nayak S; Kishor K; Sharon A
    Curr Med Chem; 2022; 29(4):666-681. PubMed ID: 33992054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.